4 not yet recruiting, 2 recruiting, 1 active not recruiting. 4 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Not yet recruiting 2, Active not recruiting 1, Recruiting 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Muscle-Invasive Bladder Cancer (MIBC): new trials by email Literature Review of Muscle-Invasive Bladder Cancer (MIBC) trials Research Report on Muscle-Invasive Bladder Cancer (MIBC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-Invasive Durvalumab, Gemcitabine, Cisplatin - Muscle-Invasive Bladder Cancer (MIBC) | Phase 4 | Not yet recruiting | AstraZeneca | 50 | 2026-10-20 | 2026-10-15 |
| Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer Trastuzumab Rezetecan, Adebrelimab, Concurrent Bladder Radiotherapy - Muscle-Invasive Bladder Cancer (MIBC) | Phase 2 | Not yet recruiting | Tongji Hospital | 70 | 2026-09-01 | 2026-10-08 |
| Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma Trastuzumab Rezetecan plus Camrelizumab - Muscle-Invasive Bladder Cancer (MIBC), Urinary Bladder Cancer | Phase 2 | Not yet recruiting | Sheng Tai | 44 | 2026-06-05 | 2026-06-10 |
| Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer Trastuzumab Rezetecan Combined with Adebelizumab - Muscle-Invasive Bladder Cancer (MIBC) | Phase 2 | Active not recruiting | Harbin Medical University | 58 | 2026-06-01 | 2026-10-19 |
| Tumor Budding and T1 Substaging in Urothelial Bladder Cancer Urothelial Bladder Carcinoma, Bladder Carcinoma | Not yet recruiting | Assiut University | 100 | 2026-05-01 | 2026-04-14 | |
| Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma | Recruiting | AZ Sint-Lucas Gent | 70 | 2025-11-07 | 2026-08-10 | |
| EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC enfortumab vedotin (EV), Toripalimab, Gemcitabine (Chemotherapy) - Muscle-Invasive Bladder Cancer (MIBC) | Phase 2 | Recruiting | Peking University Third Hospital | 58 | 2025-04-15 | 2026-06-15 |
Carcinoma, Transitional Cell (2) · Urinary Bladder Neoplasms (2) · Disease Progression (1) · Neoplasm, Residual (1) · Non-Muscle Invasive Bladder Neoplasms (1)
Neoplasms (4) · Carcinoma (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Male Urogenital Diseases (2) · Neoplasms by Site (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Urinary Bladder Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2) · Urologic Neoplasms (2)
Cisplatin (2) · Gemcitabine (2) · Drug Therapy (1) · Transurethral Resection of Bladder (1) · camrelizumab (1) · durvalumab (1) · enfortumab vedotin (1) · toripalimab (1)
AZ Sint-Lucas Gent (1) · Assiut University (1) · AstraZeneca (1) · Harbin Medical University (1) · Peking University Third Hospital (1) · Sheng Tai (1) · Tongji Hospital (1)
China (3) · Belgium (1)
Hanjiang Xu (1) · Shaogang Wang (1) · Sheng Tai (1)